Last reviewed · How we verify
NCT07208487
Clinical Study of Pretreatment PET/CT Parameters for Predicting the Efficacy of 125I Seed Implantation in the Treatment of Malignant Tumors
trial in Malignant Tumors in 41 participants. Completed in 1 December 2024.
1 November 2024
Quick facts
| Lead sponsor | Jiangxi Provincial Cancer Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 41 |
| Start date | 1 January 2019 |
| Primary completion | 1 November 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across China |
Conditions studied
- Malignant Tumors — all drugs for Malignant Tumors →
Sponsor
Jiangxi Provincial Cancer Hospital
Who can join
Eligibility, any sex, with Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to determine if pre-treatment 18F-FDG PET/CT metabolic parameters could predict the effectiveness of 125I seed implantation for malignant tumors. In a retrospective analysis of 41 patients with 69 lesions, various parameters were measured. The results identified Metabolic Tumor Volume (MTV) as the most significant independent prognostic factor, outperforming other standardized uptake values (SUV) and ratios. A higher MTV was associated with a worse treatment outcome, suggesting it is a valuable predictor for guiding treatment decisions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07208487
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Tumors
Currently open trials in the same condition.
- NCT07112222 — A Study of LM-350 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT07301801 — Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors · EARLY_PHASE1 · recruiting
- NCT07004244 — Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies · Phase 1 · recruiting
- NCT06944444 — A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT05714748 — Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors · Phase 1 · active not recruiting
Other Jiangxi Provincial Cancer Hospital trials
Trials by the same sponsor.
- NCT07314255 — The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma · active not recruiting
- NCT07277764 — Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc · Phase 2 · recruiting
- NCT07085988 — Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
- NCT06770699 — Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07208487 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangxi Provincial Cancer Hospital
- Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07208487.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing